Dale Greiner to Graft vs Host Disease
This is a "connection" page, showing publications Dale Greiner has written about Graft vs Host Disease.
Connection Strength
1.095
-
King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009 Jul; 157(1):104-18.
Score: 0.305
-
Bigazzi PE, Kosuda LL, Hannigan MO, Whalen B, Greiner DL. Lack of graft-versus-host-like pathology in mercury-induced autoimmunity of Brown Norway rats. Clin Immunol. 2003 Nov; 109(2):229-37.
Score: 0.206
-
Brehm MA, Kenney LL, Wiles MV, Low BE, Tisch RM, Burzenski L, Mueller C, Greiner DL, Shultz LD. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019 03; 33(3):3137-3151.
Score: 0.146
-
Ali R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP. Genetically modified human CD4(+) T cells can be evaluated in?vivo without lethal graft-versus-host disease. Immunology. 2016 08; 148(4):339-51.
Score: 0.125
-
Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL, Shultz LD. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol. 2010; 602:105-17.
Score: 0.079
-
Turgeon NA, Banuelos SJ, Shultz LD, Lyons BL, Iwakoshi N, Greiner DL, Mordes JP, Rossini AA, Appel MC. Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice. Exp Biol Med (Maywood). 2003 Oct; 228(9):1096-104.
Score: 0.051
-
Seung E, Mordes JP, Rossini AA, Greiner DL. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest. 2003 Sep; 112(5):795-808.
Score: 0.051
-
Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, Greiner DL. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood. 2000 Mar 15; 95(6):2175-82.
Score: 0.040
-
Welsh RM, Markees TG, Woda BA, Daniels KA, Brehm MA, Mordes JP, Greiner DL, Rossini AA. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol. 2000 Mar; 74(5):2210-8.
Score: 0.040
-
Buhlmann JE, Gonzalez M, Ginther B, Panoskaltsis-Mortari A, Blazar BR, Greiner DL, Rossini AA, Flavell R, Noelle RJ. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol. 1999 Apr 15; 162(8):4373-6.
Score: 0.038
-
Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, Rossini AA, Appel MC. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin Immunol. 2004 Sep; 112(3):273-83.
Score: 0.014